Stefan Woxström appointed SVP of AstraZeneca Europe and Canada

Stefan Woxström appointed SVP of AstraZeneca Europe and Canada

AstraZeneca has appointed Stefan Woxström as Senior Vice President (SVP) of AstraZeneca Europe and Canada (EUCAN). Stefan joins from AstraZeneca Japan where he held the position of Country President since January 2018. He succeeds Iskra Reic who has assumed the role of Executive Vice President, Vaccines and Immune Therapies at AstraZeneca.

As SVP of AstraZeneca EUCAN, Stefan is responsible for leading the company’s sales, marketing and commercial operations in 30 European countries and Canada. Stefan’s priorities for the region include growing the EUCAN business through the expansion of AstraZeneca’s therapy areas, as well as helping to make healthcare systems more resilient. Working from the EUCAN Headquarters in Baar, Switzerland, Stefan will support the country teams to transform healthcare delivery to achieve AstraZeneca’s ambition to deliver the greatest benefit for patients, healthcare systems and societies.

Stefan Woxström said: “I am delighted to take on this new role and look forward to working with our teams across Europe and Canada to harness the power of science and make a meaningful difference to patients, society and the planet. Patients are firmly at the centre of everything we do at AstraZeneca, and together, we can transform the future of healthcare and change lives for the better.”

Stefan has been with AstraZeneca since 1996 in various sales and commercial positions of increasing responsibility. He started as a Sales Representative in Sweden and has worked in commercial leadership roles since 2008, responsible for local and regional organisations. He has held four Country President positions over a thirteen-year period including Ukraine and the Commonwealth of Independent States (CIS), Turkey, the Nordic-Baltic region and, most recently, Japan. Stefan is originally from Sweden and holds a BSc and MSc in Business Administration & Economics from Stockholm University.